COVID-19: Lilly ramps up to beat the virus with neutralizing antibodies as scientists raise worries

Lilly has agreed (PDF) to pay $10 million upfront and committed up to $245 million for ex-China rights to co-develop and sell neutralizing antibodies from China’s Junshi Biosciences. Junshi’s lead candidate, dubbed JS016, is a recombinant fully human monoclonal antibody. The pair aims to apply to start a clinical trial in the U.S. in the second quarter.